PTP4A1 and systemic sclerosis: To evaluate the potential of PTP4A1 as a drug target for SSc, we assessed whether global inducible deletion of PTP4A1 could ameliorate disease in a model of SSc dependent on the constitutively active TGF-β receptor type I (TBRICA) and oxidative stress (20, 26).